| US 7,550,261 B2 | ||
| Method of screening for drug hypersensitivity reaction | ||
| Seth Hetherington, Alpharetta, Ga. (US); Arlene R Hughes, Durham, N.C. (US); Eric H Lai, Durham, N.C. (US); Michael Mosteller, Jr., Durham, N.C. (US); and Denise D Shortino, Durham, N.C. (US) | ||
| Assigned to SmithKline Beecham Corporation, Philadelphia, Pa. (US) | ||
| Filed on Aug. 07, 2002, as Appl. No. 10/214,023. | ||
| Claims priority of provisional application 60/336850, filed on Oct. 30, 2001. | ||
| Claims priority of provisional application 60/314026, filed on Aug. 21, 2001. | ||
| Prior Publication US 2003/0096274 A1, May 22, 2003 Prior Publication US 2007/0148641 A9, Jun. 28, 2007 |
||
| Int. Cl. C12Q 1/68 (2006.01); C12P 19/34 (2006.01); C07H 21/02 (2006.01); C07H 21/04 (2006.01) | ||
| U.S. Cl. 435—6 [435/91.1; 435/91.2; 536/24.3] | 18 Claims |
| 1. A method of identifying a male Caucasian human subject at increased risk of experiencing a hypersensitivity reaction to
a therapeutic regime of abacavir, comprising:
(a) performing a genotyping technique on a biological sample from said subject to determine whether the subject's HLA-B genotype
includes an allele selected from the HLA-B57 allele and the HLA-B*5701 allele;
(b) detecting an HLA-B57 allele or an HLA-B*5701 allele; and
(c) correlating the detection of an HLA-B57 or an HLA-B*5701 allele with an increased risk of experiencing a hypersensitivity
reaction to a therapeutic regime of abacavir compared to the risk if no HLA-B57 or HLA-B*5701 allele were detected.
|